openPR Logo
Press release

Industry experts to discuss containment solutions and ADC developments at Highly Potent Active Pharmaceutical Ingredients (HPAPI) 2019

03-01-2019 10:55 AM CET | Health & Medicine

Press release from: SMi Group

HPAPI 2019 Conference

HPAPI 2019 Conference

SMi is delighted to present its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference, taking place in London on the 13th-14th May 2019.

The global market for Highly Potent Active Pharmaceutical Ingredients has recently experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).

One of the underlying subjects of the conference is containment solutions and ADC developments where real-world examples of single use systems, containment for HPAPIs with low OELs and solutions to toxicity of ADCs will be discussed in fine detail.

The two-day conference will feature three key presentations from industry experts that will focus on this important subject, such as:

Mr Peter Marshall, Associate Engineering Director, AstraZeneca, will present on ‘Principles of pharmaceutical containment in isolator designs’, covering the following topics:
- Innovative solutions to dealing with the increasing toxicity of ADCs
- Designing single use systems
- Considerations when choosing between single use vs traditional use systems
- Real world examples of single use systems in industry

Dr Thomas Nittoli, Director, Regeneron, will present on ‘Antibody drug conjugate manufacturing – coordination of linker-payload synthesis and antibody conjugation’, covering the following topics:
- Technology transfer
- Scale-up
- Qualification
- ADC toxicology lot
- ADC GMP lot

Dr Jeff Parry, Senior Formulation Scientist, AstraZeneca, will present on ‘Adaptation of containment designs to cope with the high demands of HPAPIs’, covering the following topics:
- Overview of up to date containment manuals
- Containment for HPAPIs with low OELs
- Challenges of reconstructing new facilities in alignment with GMPs

HPAPI 2019 will feature more presentations from industry professionals to provide attendees with the expertise to overcome the challenges of the HPAPI industry. Download the brochure for the full two-day agenda and speaker line up at http://www.highlypotentapi.com

There is a £100 Early Bird discount on bookings expiring at midnight on Friday 29th March 2019. Places can be reserved at http://www.highlypotentapi.com

Highly Potent Active Pharmaceutical Ingredients 2019
Conference: 13th and 14th May 2019
Post-conference workshop: 15th May 2019
Holiday Inn Kensington Forum, London, UK

Sponsors and Exhibitors for HPAPI 2019 include: BSP Pharmaceuticals, Minakem, PCI Pharma Services, SafeBridge, and Solo Containment

SMi offer unique sponsorship, exhibition and branding packages, tailored to complement your company’s marketing strategy. Contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

---end---

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

SMi Group Ltd
Registered & Head Office: SMi Group Ltd, India House, 45 Curlew Street, London, SE1 2ND
Contact Neill Howard on nhoward@smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Industry experts to discuss containment solutions and ADC developments at Highly Potent Active Pharmaceutical Ingredients (HPAPI) 2019 here

News-ID: 1626129 • Views:

More Releases from SMi Group

Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug Discovery Conference
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK. The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines. Darren Green, Director of Computational Chemistry at GSK will be chairing at
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,

All 5 Releases


More Releases for HPAPI

Cytotoxic Drugs and HPAPI Manufacturing Market
Cytotoxic Drugs and HPAPI Manufacturing Market worth $27.1 Bn by 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large, Very Large), Scale of Operation (Preclinical, clinical, commercial), Type of Molecule (Small molecules, biologics), Type of Highly Potent
HPAPI Market Player Profiling, Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market Size Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other